Abstract:Highlights This is the first randomized, double‐blind, controlled clinical trial collecting data on the efficacy and safety of bexagliflozin compared to that of dapagliflozin in Chinese patients with type 2 diabetes mellitus. Bexagliflozin provides identical efficacy in improving key efficacy parameters including glycated hemoglobin, fasting plasma glucose, 2‐h postprandial blood glucose, and clinical response without an increase in adverse events compared with dapagliflozin. Background Bexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date. Methods This was a multicenter, randomized, double‐blind, active‐controlled trial comparing bexagliflozin to dapagliflozin for the treatment of type 2 diabetes mellitus in adults with disease inadequately controlled by metformin. Subjects (n = 406) were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. The primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2‐h‐postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated the safety profiles. Results The model‐adjusted mean change from baseline to week 24 HbA1c was −1.08% for bexagliflozin and −1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] −0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming the noninferiority of bexagliflozin. The changes from baseline in FPG, PPG, body weight, and SBP were −1.95 mmol/L, −3.24 mmol/L, −2.52 kg, and −6.4 mm Hg in the bexagliflozin arm and −1.87 mmol/L, −3.07 mmol/L, −2.22 kg, and −6.3 mm Hg in the dapagliflozin arm. Adverse events were experienced in 62.6% and 65.0% and serious adverse events affected 4.4% and 3.5% of subjects in the bexagliflozin and dapagliflozin arm, respectively. Conclusions Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.

Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial

A biweekly DPP‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

[Efficacy and Safety of Alogliptin in Treatment of Type 2 Diabetes Mellitus: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial in Mainland China].

Henagliflozin Monotherapy In Patients With Type 2 Diabetes Inadequately Controlled On Diet And Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study

733-P: Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Phase III, Randomized, Double‐blind, Placebo‐controlled Study to Evaluate the Efficacy and Safety of Teneligliptin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise

The Efficacy and Safety of Insulin Degludec Versus Insulin Glargine in Insulin-Naive Subjects with Type 2 Diabetes: Results of a Chinese Cohort from a Multinational Randomized Controlled Trial

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Uptitration in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Randomized, Open-Label, Prospective Study (Vision)

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Cetagliptin Added to Ongoing Metformin Therapy in Patients with Uncontrolled Type 2 Diabetes with Metformin Monotherapy

Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.

Empagliflozin Monotherapy with Sitagliptin As an Active Comparator in Patients with Type 2 Diabetes: a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

Efficacy and Safety of Alogliptin in Patients with Type 2 Diabetes Mellitus: A Multicentre Randomized Double‐blind Placebo‐controlled Phase 3 Study in Mainland China, Taiwan, and Hong Kong

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Retagliptin as add‚Äźon therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‚Äźblind, placebo‚Äźcontrolled, phase 3 trial

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study